<DOC>
	<DOCNO>NCT01290276</DOCNO>
	<brief_summary>The goal open-label Phase Ia study evaluate Pharmacokinetics ( PK ) profile new novel single-dose Ondansetron Pulsatile Release ( Ond-PR ) formulation normal healthy volunteer . After initial phase , investigator follow Phase Ib study determine Pharmacokinetic/Pharmacodynamic ( PK/PD ) , safety , tolerability interaction follow simultaneous administration ondansetron formulation 10 mg Methylphenidate Immediate Release ( MPh-IR ) tablet normal healthy volunteer .</brief_summary>
	<brief_title>Open-label , Normal Healthy Volunteer Clinical Trial Novel Ondansetron Formulation</brief_title>
	<detailed_description>We compare 2 different pulsatile-release formulation ondansetron , PR1 PR2 . Ond-PR1 pH-sensitive formulation Ond-PR2 osmotic-sensitive .</detailed_description>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subjects must give write informed consent participate study prior screen . Consent document subject 's dated signature countersign dated witness . Healthy nonsmoking , history , adult male and/or female volunteer age 18 45 year old Body Mass Index ( BMI ) ≥18≤32 kg/m2 . Subjects must good health determine screen medical history , physical examination , vital sign , electrocardiogram , blood chemistry , hematology , urinalysis ( U/A ) perform screen . Normal Hematology Clinical Laboratory , Results , include : Normal White Blood Cell ( WBC ) differential , Hematocrit , Hemoglobin , Platelet Counts Normal Electrocardiogram ( ECG ) measure Q wave T wave heart 's electrical cycle baseline ( QTcB ) ≤ 430 msec ( male ) ≤ 430 msec ( female ) Male and/or female subject consume 28 unit alcohol per week ( one unit alcohol equal ½ pint beer , 4 ounce wine , 1 ounce spirit ) subject significant history alcoholism drug/chemical abuse within last 2 year . Subjects must agree abstain alcohol , cola , tea , coffee , chocolate caffeinated drink food 2 day Period 1 , Day 1 throughout confinement . Subjects use tobacco product nicotinecontaining product ( include smoke cessation aid , gum patch ) within 3 month prior Day 1 . Subjects positive result test drug abuse , alcohol screening checkin . Concomitant Medications : Any drug , vitamin , counter ( OTC ) medicine nutraceuticals use within previous 7 day checkin deem clinically significant Principal Investigator ( PI ) . Subjects use drug substance know strong inhibitor strong inducer CYP 3A4/5 enzyme ( also know cytochrome P450 enzyme ) PGlycoprotein ( Pgp ) within 30 day prior Period 1 , Day 1 . Subjects must agree abstain grapefruit/grapefruit juice seville orange 2 day period Ia , Day 1 throughout study . Use investigational drug time enrollment ( consent ) , 5 halflives enrollment whichever longer ; longer require local regulation , limitation participation investigational trial base local regulation . History unstable psychiatric illness require medication hospitalization within previous 12 month . History concurrent illness require hospitalization within 14 day prior Day 1 study . Any condition clinical judgment Investigator would make subject unsuitable participation . Allergies allergic reaction product use study . Subjects clinically significant illness within 4 week prior Day 1 . Subjects QTcB interval duration &gt; 430 msec ( male ) &gt; 450 ( female ) obtain ECG recorder 's measurement screen ECG take least 5 minute quiet rest supine position . History current evidence clinically significant hepatic , renal , cardiovascular ( i.e. , deep venous thrombosis , pulmonary embolism ) , psychological , pulmonary , metabolic , endocrine , neurologic ( i.e. , transient ischemic attack stroke within past 6 month ) infectious , gastrointestinal ( i.e. , condition may affect drug absorption ) hematologic , oncologic disease , retinopathy , medical disorder , determine screen history , physical examination , laboratory test result , 12lead ECG . History unexplained syncope . Subjects creatinine clearance &lt; 80 mL/min ( base CockcroftGault equation ) . Subjects , opinion Investigator , participate study . Any employee Duke Clinical Research Unit ( DCRU ) . Subjects blood relatives another study participant . Subjects must compliant meet inclusion exclusion criterion unless , follow discussion Principal Investigator designate , determine minor exception indicative clinically significant safety risk unlikely confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Ondansetron</keyword>
	<keyword>Methylphenidate</keyword>
</DOC>